Julphar, Gulf Pharmaceutical Industries, held a Board of Directors meeting at their RAK Head Office to announce a draft financial report registering sales revenue of AED1,433.1 million during the year 2014, up 5.2 percent year-on-year. Sales during the year were driven by the private market sales which saw growth of 7.5 percent.
The company witnessed a steady operational performance during the year. Gross Profit during the year was AED848.2 million, up 3.4 percent, Operating Profit was AED238.5 million, up 1.1 percent and profit for the year was AED234.7 million, up 2.9 percent.
The Board of Directors proposed a General Assembly date of 30th April 2015, to distribute 15 percent cash and 5 percent bonus shares.
Speaking after the Board Meeting, Dr Ayman Sahli, CEO, said, "2014 was another year of great achievements for Julphar - we are pleased to close the year at AED1.4bn, which shows a remarkable effort from our global sales force and highlights true dedication from our staff across all functions, in all countries. Together, we have been working hard to deliver quality, affordable healthcare to our communities; a vision which remains at the core of our business strategy and creates overall value to the board, shareholders, staff and our customers."